

FUND STRATEGY

The Fund seeks to achieve its investment objective by investing in the common stocks of small and mid-cap companies which have the potential to deliver above-average long-term earnings growth, in which earnings and sales growth, valuation, and profitability are assessed through fundamental-based research. The Fund looks for companies which are market leaders in growth industries, have a strong brand name, and whose sales and earnings have increased at a consistent rate. The investment approach includes the analysis of company financial statements in addition to meeting with corporate managements.

PERFORMANCE

Average Annual Returns as of 09/30/17


	3 Month	YTD	1YR	3YR	5YR	10YR
Fund	5.90%	27.37%	19.67%	10.11%	12.98%	7.37%
Russell 2500 Growth Index	5.78%	17.03%	20.07%	11.27%	14.46%	8.72%

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. The performance assumes reinvestment of capital gains and dividends. Fund performance current to the most recent month-end may be lower or higher than the performance quoted and can be obtained by calling 1-800-697-3863 or visiting www.tocquevillefunds.com.

^The Advisor has contractually agreed to waive management fees and/or reimburse expenses in order to ensure that the Fund's expense ratio does not exceed 1.25% (excluding taxes, interest expense, acquired fund fees and expenses, or extraordinary expenses such as litigation) until at least 3/1/2018. In the absence of these fee waivers, total returns would be lower.

Performance for periods before 10/12/10 is for The Tocqueville Small Cap Fund, which was renamed The Tocqueville Opportunity Fund on 10/12/10. The Tocqueville Small Cap Fund had different Portfolio Managers until 7/1/10 and different investment objectives and strategies until 10/12/10.

Calendar Year Returns



QUARTERLY UPDATE

- During 3Q 2017, the Fund appreciated 5.90% and outperformed the Russell 2500 Growth Index which gained 5.78%. A significant and rapid rotation into the more cyclical sectors occurred in September, with the Energy, Industrials, Consumer Discretionary and Financials sectors leading the benchmark. The rotation was likely due to revival of tax reform proposals, and the consequent hope for increased economic stimulus. The Health Care and Technology sectors, which have powered performance over the past nine months, lagged cyclicals for September. On a calendar year-to-date basis, the Fund has gained 27.37% versus a benchmark increase of 17.03%.
- Health Care and Technology issues were the leading contributors to Fund performance during the quarter on both an absolute and a relative basis, with the two sectors responsible for nearly 90% of the Fund's increase. Nevertheless, the Fund had positive contribution from all but two sectors, including Energy, which declined modestly due to investments in airline issues. Kite Pharmaceutical was the leading contributor on both an absolute/relative basis. Gilead Sciences offered to buy the company for cash at \$180 per share. Other significant contributors included Spark Therapeutics, NVIDIA Corp, and bluebird bio. The Fund was most impacted by sell-offs in Clovis Oncology and SAGE Therapeutics; however Clovis has gained 86% year-to-date due to approval of its ovarian cancer therapies and SAGE has gained 22% year-to-date.
- At the end of the quarter, the Top 10 and Top 25 investments comprised 35% and 59% respectively of the Fund's portfolio, while the Top 100 investments comprised 92%. We held no investments in Energy, Consumer Staples, Utilities or Telecommunications at quarter end, versus the benchmark's weighting of approximately 5% in total for these same sectors.

FUND OBJECTIVE

The Tocqueville Opportunity Fund's investment objective is long-term capital appreciation.

FUND FACTS

Symbol:	TOPPX
Cusip:	888894409
Dividend Policy:	Annual
Minimum Investment:	\$1,000 (\$250 IRA)
Total Fund Assets:	\$75.2 million
Annual Fund Operating Expenses:	1.39%
Fee Waiver/Expense Reimbursement: [^]	-0.13%
Annual Fund Operating Expenses after Fee Waiver/Expense Reimbursement:	1.26%
Sales Charge:	None
Inception Date:	8/1/1994
Manager's Tenure:	7 Years
Morningstar Category:	Mid-Cap Growth

ASSET ALLOCATION


	% of Net Assets
Equities:	97.81%
Purchased Call Options:	1.46%
Exchange-Traded Funds:	0.87%
Real Estate Investment Trusts:	0.04%
Cash Equivalents, Other Liabilities, and Payables:	-0.18%

PORTFOLIO STATISTICS

Total # Holdings:	190
P/E:	37.6x
Weighted Median Market Cap:	\$7.0 B
Weighted Avg. Market Cap:	\$22.6 B
Turnover Ratio:	141%

SECTOR ALLOCATION

% OF EQUITIES



TOP TEN HOLDINGS

% OF NET ASSETS

NVIDIA Corp.	5.71%
Bluebird Bio, Inc.	3.93%
ServiceNow, Inc.	3.75%
Spark Therapeutics, Inc.	3.74%
TESARO, Inc.	3.26%
Paylocity Holdings Corp.	3.08%
Workday, Inc. - Class A	3.08%
Incyte Corp.	3.03%
Aerie Pharmaceuticals, Inc.	2.65%
New Relic, Inc.	2.55%
Total	34.78%

Fund holdings and sector weightings are subject to change at any time and are not recommendations to buy or sell any security. Holdings are based on percent of net assets.

PORTFOLIO MANAGER



Thomas Vandeventer is the portfolio manager of the Tocqueville Opportunity Fund and has been since July 2010. Prior to joining Tocqueville in 2006, Mr.

Vandeventer was Senior Managing Director and head of the Institutional Large Cap Growth group at Clearbridge Advisors (Legg Mason) and Citigroup Global Asset Management (CAM). Mr. Vandeventer has a BA from the University of Virginia in 1978 and an MBA from Columbia University in 1983.

Investors should carefully consider investment objectives, risks, charges and expenses. This and other important information is contained in the fund prospectus which should be considered carefully before investing.

Distributed by Tocqueville Securities L.P.

GLOSSARY OF TERMS

P/E: The weighted average of the price/earnings (P/E) ratios of the equity securities referenced. The P/E ratio is calculated by dividing the current price of the stock by the trailing earnings per share for the past 12 months.

The Russell 2500 Growth Index measures the performance of the small to mid-cap growth segment of the U.S. equity universe. It includes those Russell 2500 companies with higher price-to-book ratios and higher forecasted growth values. You cannot invest directly in an index.

The Morningstar Mid Cap Growth Portfolios feature firms that are projected to grow faster than other mid-cap stocks. The U.S. mid cap range for market capitalization typically falls between \$1 billion and \$8 billion and represents 20% of the total capitalization of the U.S. equity market. Growth is defined based on fast growth (high growth rates for earnings, sales, book value, and cash flow) and high valuations (high price ratios and low dividend yields).

DISCLOSURES

Mutual Fund investing involves risk. Principal loss is possible. **Past performance is not a guarantee of future results.** The Fund invests in smaller companies, which involve additional or special risks such as small companies rely on limited product lines, financial resources and business activities that may make them more susceptible than larger companies to setbacks or downturns; and small cap stocks are less liquid and more thinly traded which make them more volatile than stocks of larger companies.

The Tocqueville Mutual Funds may be offered only to persons in the United States. This literature should not be considered a solicitation or offering of any investment products or services to investors residing outside of the United States.